Global Market For Liver Disease Treatment Rise In Healthcare Investment Over The Period 2017 - 2021

Researchmoz added Most up-to-date research on "Global Market For Liver Disease Treatment Rise In Healthcare Investment Over The Period 2017 - 2021" to its huge collection of research reports.

Liver is the largest organ of the body and can completely recover from damage. However, continuous strain on the liver, when treatment is delayed, for a prolonged period of time can lead to severe damage to the liver and can even be fatal.

Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as India and China has led to a higher prevalence of the disease in these countries. There has been a rise in healthcare investment in these countries.

Technavios analysts forecast the global liver disease treatment market to grow at a CAGR of 11.01% during the period 2017-2021.

Covered in this report The report covers the present scenario and the growth prospects of the global liver disease treatment market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs in liver disease treatment market.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Liver Disease Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffmann-la Roche
Gilead
GlaxoSmithKline
Merck

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1249630

Other prominent vendors
Bristol-Myers Squibb
Johnson and Johnson
Novartis
Salix Pharmaceuticals
Vertex Pharmaceuticals

Market driver
Increase in alcohol-related liver disease
For a full, detailed list, view our report

Market challenge
Side-effects of liver disease treatment drugs
For a full, detailed list, view our report

Market trend
Rise in awareness
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Browse More Details @ http://www.researchmoz.us/global-liver-disease-treatment-market-2017-2021-report.html

Symptomatic Treatments On Parkinsons Disease - Heat Map and Analysis

Researchmoz added Most up-to-date research on "Symptomatic Treatments On Parkinsons Disease - Heat Map and Analysis" to its huge collection of research reports.

Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties, and progress in varying stages.

There is currently no cure for PD, with inadequate symptomatic treatments on the market that are suboptimal in terms of efficacy. The most urgent unmet need is the lack of disease-modifying therapies that demonstrate neuroprotective properties to prevent or at least significantly slow neuronal cell death. Significant efforts have been made to develop new treatments to address this need.

The differences between many of these products lie in their mechanisms of action, which must be fully understood by companies looking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the PD market and Phase III pipeline. These are split by classes of therapy.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population, are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

• What are the clinical characteristics of currently approved therapies for PD, in terms of specific safety and efficacy parameters?
• What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
• How will current late-stage molecules affect the market for levodopa therapies, and are they able to yield comparable clinical efficacy results?
• Will the market benefit from any disease-modifying therapies in the near future?

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=970727

Reasons to buy

• Understand the current clinical landscape by considering the treatment options available by drug class.
• Visually compare the currently approved treatments available by drug class, based on the most important efficacy and safety parameters tested in clinical trials.
• Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
• Understand the relative strengths and weaknesses of the studies used to gather these data.
• Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
• Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Table of Contents

1 Table of Contents
1 Table of Contents 2

2 Introduction 3
2.1 Report Guidance 4

3 Marketed Products 5
3.1 Levodopa-plus-Carbidopa-Based Treatments 5
3.2 Dopamine Agonists 7
3.3 Monoamine Oxidase-B Inhibitors 9
3.4 Catechol-O-methyltransferase Inhibitors 10
3.5 Alternative Treatments 11

4 Pipeline Products 14
4.1 Changes to Levodopa-plus-Carbidopa-Based Treatment, 2016–2022 14
4.2 Changes to Alternative Treatments, 2016–2022 15

Browse More Details @ http://www.researchmoz.us/parkinsons-disease-heat-map-and-analysis-report.html

Clinical Trials On Chronic Kidney Disease (CKD) Drugs In Global Market During The Forecast Period 2016 - 2024

Researchmoz added Most up-to-date research on "Clinical Trials On Chronic Kidney Disease (CKD) Drugs In Global Market During The Forecast Period 2016 - 2024" to its huge collection of research reports.

This report on the global chronic kidney disease (CKD) drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global chronic kidney disease (CKD) drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the chronic kidney disease (CKD) drugs market such as novel treatment approaches such as monoclonal antibodies, RNA-based therapies and stem cell based therapies. The key market indicators influencing global Chronic Kidney Disease (CKD) Drugs market taken into consideration including cost constraints and regulatory landscape. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global Chronic Kidney Disease (CKD) Drugs market. The report also highlights key events of the global Chronic Kidney Disease (CKD) Drugs industry. A porter’s five force analysis highlighting competitive landscape is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global Chronic Kidney Disease (CKD) Drugs market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and cost reduction for hospitals and greater affordability for patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Global Chronic Kidney Disease (CKD) Drugs Market: Segmentation
Based on product type, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into ACE Inhibitors, Angiotensin-II receptor blockers, Calcium channel blockers, Beta blockers, Erythropoiesis-stimulating agents (ESAs), Diuretics, and Others. Based on end-user, the market has been segmented into hospitals and specialty clinics. Hospitals segment is expected to remain dominant during the forecast period.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1056467

Geographically, the global Chronic Kidney Disease (CKD) Drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Global Chronic Kidney Disease (CKD) Drugs Market: Competitive Landscape
The report also profiles major players in the Chronic Kidney Disease (CKD) Drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the Chronic Kidney Disease (CKD) Drugs market is provided in the report. Key companies profiled in the report include Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, AbbVie, Inc., GlaxoSmithKline plc., Sanofi S.A. , F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca plc, Amgen Inc., and Teva Pharmaceutical Industries Ltd.

The global Chronic Kidney Disease (CKD) Drugs market has been segmented as follows:

By Drug class

• ACE Inhibitors
• Angiotensin-II receptor blockers
• Calcium channel blockers
• Beta blockers
• Erythropoiesis-stimulating agents (ESAs)
• Diuretics
• Others

By End User

• Hospitals
• Specialty Clinics

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Spain
• Italy

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1056467

Detailed Analysis & Symptoms Of Alzheimers Disease | ResearchMoz

Researchmoz added Most up-to-date research on "Detailed Analysis & Symptoms Of Alzheimers Disease | ResearchMoz" to its huge collection of research reports.

Alzheimers disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. The pathological features of AD comprise a complex set of histopathological changes within the brain. Symptoms typically begin to first appear in patients in their mid-sixties, and appear in varying stages. The effects of AD, particularly at an advanced stage, are devastating to patients and their caregivers, and are associated with significant associated healthcare costs.

Current treatments focus on sustaining the patient?s cognitive function, managing behavioural symptoms and slowing down the rate of disease progression. There is currently no cure for AD, and only six symptomatic treatment therapies have been approved, of which one (Cognex) is no longer available in the US. The current market leaders are suboptimal in terms of efficacy, and there is therefore a large unmet need within AD to develop safer and more efficacious treatments.

There are numerous differences between many of these products due to their mechanisms of action, and these must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the AD market and Phase III pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=915814

Scope

• What preventative early-stage drugs are generating interest within the AD pipeline? 
• Will the current AD market landscape ensure that the first drug with a disease-modifying mechanism of action will become the market leader?
• What are the clinical characteristics of currently approved therapies for AD, in terms of specific safety and efficacy parameters?
• What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
• How will current late-stage molecules affect the market for AChEIs, and are they able to yield comparable clinical efficacy results?
• With three amyloid inhibitors present in the late-stage pipeline, do they have sufficient differentiating characteristics from previous clinical failures from this class to have an impact on the market?

Reasons to buy

• Understand the current clinical landscape by considering the treatment options available by drug class.
• Visually compare the currently approved treatments available by drug class, based on the most important efficacy and safety parameters tested in clinical trials.
• Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy
• Understand the relative strengths and weaknesses of the studies used to gather these data.
• Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
• Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=915814

Functioning Of Primary Immunodeficiency Disease In Global Market During The Forecast Period 2014 - 2020

Researchmoz added Most up-to-date research on "Functioning Of Primary Immunodeficiency Disease In Global Market During The Forecast Period 2014 - 2020" to its huge collection of research reports.

Abnormal functioning of immune system due to lack of necessary antibodies or lack of normal functioning of present antibodies is referred as primary immunodeficiency disease. Immunodeficiency is referred as primary immunodeficiency when any disease, environmental exposure to toxins or drug treatment is not the cause of the disease. Primary immunodeficiency disease is also referred as primary immune disorder or primary immunodeficiency disorder. Approximately one in every 500 people is observed to have primary immunodeficiency disease. 

Primary immunodeficiency disease is a genetic disorder. Signs and symptoms of primary immunodeficiency disorder include recurrent bronchitis, pneumonia, meningitis, and ear infection. In addition, sinus infection, blood infection, skin infection, infection of internal organs, inflammation, and delayed development and growth are also observed. In addition, loss of appetite, diarrhea, nausea, cramping, digestive problems, blood disorders including, anemia, and low platelet count are also observed in some cases. Immunodeficiency disorder is commonly diagnosed in infants. However, mild form of primary immunodeficiency may not be diagnosed until adulthood. Based on the types, the global primary immunodeficiency disorder market is segmented as follows:

• B cell (antibody) deficiencies
• T cell deficiencies
• Combination B and T cell deficiencies
• Defective phagocytes
• Combination B and T cell deficiencies
• Complement deficiencies
• Unknown (idiopathic)

Based on the diagnostic tests, global primary immunodeficiency disorder market is segmented as follows:

• Blood Tests
• Prenatal Testing
• DNA Testing
• Tissue and Placental Sample Testing 
• Others

Based on the treatment, global primary immunodeficiency disorder market is segmented as follows:

• Antibiotics for Treating Symptoms
• Treatment to Boost the Immune System
  • Immunoglobulin Therapy
  • Gamma Interferon Therapy
  • Growth Factors

• Treatment to Cure Primary Immunodeficiency
• Stem Cell Transplantation

Geographically, the global primary immunodeficiency disorder market is segmented as North America, Europe, Asia-Pacific, and Rest of the World (RoW) regions. Presently, North America is dominating the global primary immunodeficiency disorders market. Europe is the second largest market in the overall primary immunodeficiency disease market. Exceptionally developed healthcare infrastructure, reimbursement coverage, higher healthcare spending, availability of advanced healthcare technology, and high rate of awareness about primary immunodeficiency disease are few of the major factors that are driving the growth of the primary immunodeficiency disease market in North America and Europe. Asia-Pacific is a lucrative market for primary immunodeficiency diseases market. 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=223169

Rapidly developing healthcare infrastructure, increasing disposable income and government initiatives to improve healthcare industry in respective country on the ground of rapidly growing medical tourism industry are some of the factors that are driving the growth of primary immunodeficiency disease market in Asia-Pacific. China and India are expected to grow swiftly owing to rapidly developing medical tourism industry in these countries. Apart from China and India, Japan is expected to contribute in the growth of the primary immunodeficiency disease market in Asia due to increased focus of Japanese government to offer improved and advanced healthcare facilities to Japanese citizens. Mexico, Brazil, and Argentina are the countries in the Rest of the World (RoW) region that are expected to demonstrate faster growth in the primary immunodeficiency market than African countries. Middle Eastern countries along with rest of the Latin American countries are expected to be second fastest growing markets for the primary immunodeficiency disease in the Rest of the World (RoW) region. 

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of 

• Market growth drivers 
• Factors limiting market growth
• Current market trends 
• Market structure
• Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth 
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow 
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=223169

Healthcare Industry For Polycystic Kidney Disease - Pipeline Review, H1 2017

Researchmoz added Most up-to-date research on "Healthcare Industry For Polycystic Kidney Disease - Pipeline Review, H1 2017" to its huge collection of research reports.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2017, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. 

Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1068458

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1068458

Cardiovascular Disease Global Market Till 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

ResearchMoz presents this most up-to-date research on "Cardiovascular Disease Global Market Till 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth".

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.

Scope

• Analysis of innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events.
• A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.
• Identification of key marketed products, with a focus on historical and forecast sales patterns and an overview of each drug’s mechanism of action.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=869174

• Comprehensive review of the pipeline, analyzed on the basis of stage of development, molecule type and molecular target.
• In-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries and drug patent expirations will influence market value.

Reasons to buy

This report will allow you to 

• Understand the current clinical and commercial landscape through a comprehensive analysis of the innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events
• Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the drug’s mechanism of action.
• Analyze the CVD pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at CVD clinical trials as to provide an insight into the risk associated with attempting to bring CVD pipeline drugs.
• Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=869174

Major Symptoms Of Global Foot and Mouth Disease (FMD) Vaccines Market (By Types: Conventional Vaccines and Emergency Vaccines, and By Applications: Cattle, Pigs, Sheep and Goats and Others): 2017 - 2020

ResearchMoz presents this most up-to-date research on "Major Symptoms Of  Global Foot and Mouth Disease (FMD) Vaccines Market (By Types: Conventional Vaccines and Emergency Vaccines, and By Applications: Cattle, Pigs, Sheep and Goats and Others): 2017 - 2020".

Foot-and-mouth disease (FMD) is an infection caused by aphthovirus belonging to the family Picornaviridae. FMD is caused by seven different types of serotypes: O, A, C, Asia 1 and Southern African Territories (SAT) 1, 2 and 3. Currently available vaccines are serotype-specific, hence multiple vaccinations are required to cover the antigenic diversity. Cloven-hoofed animals especially cattle, pigs, sheep and goats are susceptible to FMD. The major symptoms of FMD are high fever, sudden weight loss, increased death rate in newborn animals, low conception rate, painful lesions in and around mouth, lips and feet, and excessive salivation. High frequency of FMD outbreaks especially in Asia, the Middle East, and Latin America is fueling the demand for FMD vaccines. In addition, government initiatives to eradicate the disease is resulting in increased awareness about FMD vaccines, thereby driving market growth. This report covers the market analysis of various types of vaccines that are used to control FMD.

The executive summary of the report comprises market snapshot of the global foot-and-mouth disease vaccines market and comparative analysis by geography in terms of value % for 2013 and 2020. The global foot-and-mouth disease vaccines market has been segmented based on types of vaccines: conventional and emergency vaccines. The conventional vaccines segment has been sub-segmented based on adjuvants: aluminum hydroxide/saponin and oil-based vaccines. In-depth market analysis and forecast for all the segments mentioned above has been provided in the report, in terms of market revenue (USD million) from 2012 to 2020. The report includes the compounded annual growth rate (CAGR %) for each application segment (cattle, pigs, sheep and goat and others) for the forecast period from 2014 to 2020, considering 2013 as the base year.  

The market overview section of the foot-and-mouth disease vaccines market report analyzes the market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the global FMD vaccine market. Impact factors such as market attractiveness analysis by geography and Porter’s five forces (bargaining power of suppliers, bargaining power of buyers, threat of new entrants, threat of substitutes and competitive rivalry) analysis of the global foot-and-mouth disease vaccines market have been provided in this section of the report. In addition, market share analysis of key players (value %) for the year 2013 has also been explained in the market overview section of the report in order to provide a thorough analysis of the overall competitive scenario in the global FMD vaccines market. Furthermore, the report includes value chain analysis and regulatory framework analysis of the FMD vaccines market. 

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=209072

Geographically, the global FMD vaccines market has been classified into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The current and future market sizes (in terms of USD million) of the regional markets mentioned above have been provided in the report for the period from 2012 to 2020 along with the growth rate (CAGR %) for the period from 2014 to 2020. The study further offers recommendations for the foot-and-mouth disease vaccines market, which would be useful for existing and new players to sustain and grow in the market. 

The foot-and-mouth disease vaccines market report concludes with the company profiles section that includes key information in terms of company overview, financial information, product portfolio, business strategies and recent development about the major players operating in the FMD vaccines market. Detailed analysis of these companies is included in this section in order to give a thorough analysis of the overall competitive scenario in the global FMD vaccines market. Key players profiled in the section include Agrovet Co., Bayer AG, Biogenesis Bagó, Brilliant Bio Pharma Limited, Indian Immunologicals Ltd., Inova Biotechnologia, Intervac (Pvt.) Ltd., Merial, and Merck Animal Health (MSD). 

The global foot and mouth disease vaccines market is segmented as follows:

Foot and Mouth Disease Vaccines Market, by Types

• Conventional Vaccines
• Aluminum Hydroxide/Saponin
• Oil Based
• Emergency Vaccines

Foot and Mouth Disease Vaccines Market, by Applications

• Cattle
• Pigs
• Sheep and Goats
• Others

Foot and Mouth Disease Vaccines Market, by Geography

• North America
• Europe 
• Asia-Pacific
• Rest of the World 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=209072

Global Foot and Mouth Disease (FMD) Vaccines Industry: Emerging Trends and Opportunities To 2017

Researchmoz added Most up-to-date research on "Global Foot and Mouth Disease (FMD) Vaccines Industry: Emerging Trends and Opportunities To 2017" to its huge collection of research reports.

The Global Foot and Mouth Disease (FMD) Vaccines Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Foot and Mouth Disease (FMD) Vaccines industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Foot and Mouth Disease (FMD) Vaccines market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.The Foot and Mouth Disease (FMD) Vaccines industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

With 180 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=313415

Table Of Content

1 Industry Overview

1.1 Definition and Specifications of Foot and Mouth Disease (FMD) Vaccines

1.2 Classification of Foot and Mouth Disease (FMD) Vaccines

1.3 Applications of Foot and Mouth Disease (FMD) Vaccines

1.4 Industry Chain Structure of Foot and Mouth Disease (FMD) Vaccines

1.5 Industry Regional Overview of Foot and Mouth Disease (FMD) Vaccines

1.6 Industry Policy Analysis of Foot and Mouth Disease (FMD) Vaccines

1.7 Industry News Analysis of Foot and Mouth Disease (FMD) Vaccines

2 Manufacturing Cost Structure Analysis of Foot and Mouth Disease (FMD) Vaccines

2.1 Raw Material Suppliers and Price Analysis of Foot and Mouth Disease (FMD) Vaccines

2.2 Equipment Suppliers and Price Analysis of Foot and Mouth Disease (FMD) Vaccines

2.3 Labor Cost Analysis of Foot and Mouth Disease (FMD) Vaccines

2.4 Other Costs Analysis of Foot and Mouth Disease (FMD) Vaccines

2.5 Manufacturing Cost Structure Analysis of Foot and Mouth Disease (FMD) Vaccines

2.6 Manufacturing Process Analysis of Foot and Mouth Disease (FMD) Vaccines

3 Technical Data and Manufacturing Plants Analysis

3.1 Capacity and Commercial Production Date of Global Key Manufacturers in 2014

3.2 Manufacturing Plants Distribution of Global Key Foot and Mouth Disease (FMD) Vaccines Manufacturers in 2014

3.3 R&D Status and Technology Source of Global Foot and Mouth Disease (FMD) Vaccines Key Manufacturers in 2014

3.4 Raw Materials Sources Analysis of Global Foot and Mouth Disease (FMD) Vaccines Key Manufacturers in 2014

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=313415

Foot-and-mouth Disease (FMD) Vaccine Industry In Europe For 2017

Researchmoz added Most up-to-date research on "Foot-and-mouth Disease (FMD) Vaccine Industry In Europe For 2017" to its huge collection of research reports.

The Europe Foot-and-mouth Disease (FMD) Vaccine Industry Report 2015 is a professional and in-depth study on the current state of the Foot-and-mouth Disease (FMD) Vaccine industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Foot-and-mouth Disease (FMD) Vaccine market analysis is provided for the Europe markets including development trends, competitive landscape analysis, and key regions development status. 

Development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on Europe major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Foot-and-mouth Disease (FMD) Vaccine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. 

With 172 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=350025

Table Of Content

Chapter One Industry Overview

1.1 Definition and Specifications of Foot-and-mouth Disease (FMD) Vaccine

1.2 Classification of Foot-and-mouth Disease (FMD) Vaccine

1.3 Applications of Foot-and-mouth Disease (FMD) Vaccine

1.4 Industry Chain Structure of Foot-and-mouth Disease (FMD) Vaccine

1.5 Industry Overview of Foot-and-mouth Disease (FMD) Vaccine

1.6 Industry Policy Analysis of Foot-and-mouth Disease (FMD) Vaccine

1.7 Industry News Analysis of Foot-and-mouth Disease (FMD) Vaccine

Chapter Two Manufacturing Cost Structure Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.1 Bill of Materials(BOM) of Foot-and-mouth Disease (FMD) Vaccine

2.2 BOM Price Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.3 Labor Cost Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.4 Depreciation Cost Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.5 Manufacturing Cost Structure Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.6 Manufacturing Process Analysis of Foot-and-mouth Disease (FMD) Vaccine

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=350025

China’s Foot-and-mouth Disease (FMD) Vaccine Industry: Emerging Trends and Opportunities To 2017

Researchmoz added Most up-to-date research on "China’s Foot-and-mouth Disease (FMD) Vaccine Industry: Emerging Trends and Opportunities To 2017" to its huge collection of research reports.

The China Foot-and-mouth Disease (FMD) Vaccine Industry Report 2015 is a professional and in-depth study on the current state of the Foot-and-mouth Disease (FMD) Vaccine industry.

The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Foot-and-mouth Disease (FMD) Vaccine market analysis is provided for the China markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and Bill of Materials cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on China major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Foot-and-mouth Disease (FMD) Vaccine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. 

With 172 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=350031

Table Of Content

Chapter One Industry Overview

1.1 Definition and Specifications of Foot-and-mouth Disease (FMD) Vaccine

1.2 Classification of Foot-and-mouth Disease (FMD) Vaccine

1.3 Applications of Foot-and-mouth Disease (FMD) Vaccine

1.4 Industry Chain Structure of Foot-and-mouth Disease (FMD) Vaccine

1.5 Industry Overview of Foot-and-mouth Disease (FMD) Vaccine

1.6 Industry Policy Analysis of Foot-and-mouth Disease (FMD) Vaccine

1.7 Industry News Analysis of Foot-and-mouth Disease (FMD) Vaccine

Chapter Two Manufacturing Cost Structure Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.1 Bill of Materials(BOM) of Foot-and-mouth Disease (FMD) Vaccine

2.2 BOM Price Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.3 Labor Cost Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.4 Depreciation Cost Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.5 Manufacturing Cost Structure Analysis of Foot-and-mouth Disease (FMD) Vaccine

2.6 Manufacturing Process Analysis of Foot-and-mouth Disease (FMD) Vaccine

Chapter Three Technical Data and Manufacturing Plants Analysis

3.1 Capacity and Commercial Production Date of China Key Manufacturers in 2014

3.2 Manufacturing Plants Distribution of China Key Foot-and-mouth Disease (FMD) Vaccine Manufacturers in 2014

3.3 R&D Status and Technology Source of China Foot-and-mouth Disease (FMD) Vaccine Key Manufacturers in 2014

3.4 Raw Materials Sources Analysis of China Foot-and-mouth Disease (FMD) Vaccine Key Manufacturers in 2014

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=350031

2017 - 2019: Research Report on Foot-and-mouth Disease (FMD) Vaccine Industry In China

Researchmoz added Most up-to-date research on "2017 - 2019: Research Report on Foot-and-mouth Disease (FMD) Vaccine Industry In China" to its huge collection of research reports.

Picornavirus, the prototypic member of the genus Aphthovirus, is the virus responsibal for FMD. And it has seven serotypes with different antigenicity. The disease is characterized by high fever that declines rapidly after two or three days, blisters inside the mouth that lead to excessive secretion of stringy or foamy saliva and to drooling, and blisters on the feet that may rupture and cause lameness. Adult animals may suffer weight loss from which they do not recover for several months, as well as swelling in the testicles of mature males, and in cows, milk production can decline significantly. Though most animals eventually recover from FMD, the disease can lead to myocarditis and death, especially in newborn animals. Some infected ruminants remain asymptomatic carriers, but they nonetheless carry FMDV and may be able to transmit it to others.

The transmission of FMD is generally regional. The FMD virus can be transmitted in a number of ways including close-contact animal-to-animal spread, or inanimate objects, typically stall and vehicles. The clothes and skin of animal handlers such as farmers, standing water and uncooked food straps and feed supplements containing infected animal products can harbor the virus, as well. Cows can also catch FMD from the semen of infected bulls. Control measures include quarantine and destruction of infected livestock, and export bans for meat and other animal products to countries not infected with the disease.

Table of Content

China Research and Intelligence Co., Ltd.
1.1 Related Concepts of FMD Vaccine
1.1.1 Definition of FMD
1.1.2 Definition of FMD Vaccine
1.2 Introduction to FMD Outbreak
1.2.1 Occurrence of FMD
1.2.2 FMD Outbreak in China

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=449902

2 Factors Affecting Development of FMD Vaccine in China, 2011-2015
2.1 Chinese Policy for Animal Vaccine Industry
2.1.1Epidemic prevention Legistration
2.1.2 Institutions
2.1.3 Epidemic Prevention Budget
2.1.4 Scope of Compulsory Immunity
2.1.5 FMD Immunization Program
2.2 Overview of Stock Raising Industry in China in 2014
2.2.1 State of Pig Raising
2.2.2 State of Cattle Raising
2.2.3 State of Sheep Raising

3 Operation Status of FMD Vaccine Industry in China, 2010-2014
3.1 Supply of FMD Vaccine
3.1.1 Supply Overview
3.1.2 Factors Affecting Supply
3.2 Demand
3.2.1 Demand Overview
3.2.2 Factors Affecting Demand
3.3 FMD Vaccine Provided by the Government for Free
3.3.1 Analysis of Existing Problems
3.3.2 Solutions to Problems

4 Major Producers of FMD Vaccine in China, 2011-2015
4.1 CAHIC
4.1.1 Company Profile
4.1.2 Production of FMD Vaccine
4.1.3 Development Strategy
(4.2-4.7 are Structured the Same as 4.1)
4.2 The Spirit Jinyu Biological Pharmaceutical Co., Ltd
4.3 TECON
4.4 China Agricultural Vet.Bio. Science and Technology Co., Ltd
4.5 Inner Mongolia Bi Wei Antai Biological Technology Co., Ltd
4.6 Shen Lian Biotechnology Co., Ltd
4.7 QYH Biotech Co., Ltd

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=449902